Alopecia Areata, Atopic Dermatitis, Hidradenitis Suppurativa (HS), Vitiligo
Conditions
Keywords
Dermatologic Disease, DERM+
Brief summary
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Detailed description
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them. TARGET-DERM+ is designed to develop a large, robust database of real-world data regarding the natural history, management, and health outcomes related to the care of DD of diverse etiologies and practice settings. The study is also designed to establish learning health networks focused on quality of care for patients with DD.
Interventions
None listed
Sponsors
Target PharmaSolutions, Inc.
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants. * Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.
Exclusion criteria
* Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease | 15 years | The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for DD |
| To characterize the natural history of disease in patients with dermatologic disease from various etiologies | 15 years | A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population. |
| To establish learning health networks focused on quality of care for patients | 15 years | Identify deficiencies and best practices in care of patients with DD. • Evaluate outcomes from targeted learning content in the management of patients with DD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate provider management practices in the treatment of patients with DD | 15 years | Health care provider type, clinic setting, reason for initiating/not initiating/adjusting dosing of treatments, reason for discontinuing/switching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and/or through linked data. |
| To evaluate longitudinal and patient reported outcomes in DD | 15 years | Longitudinal clinical outcomes and disease progression will be assessed. Self-reported patient health measures collect information directly from patients to measure physical, mental, and social health. |
Countries
United States
Contacts
CONTACTLynda Lee Burch
CONTACTLaura Dalfonso
STUDY_DIRECTORLaura Dalfonso
Pedestal Health
Outcome results
None listed